| Patent application number | Description | Published |
|---|
| 20110092479 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 04-21-2011 |
| 20110110889 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 05-12-2011 |
| Patent application number | Description | Published |
|---|
| 20080242656 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1) | 10-02-2008 |
| 20080261994 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 10-23-2008 |
| 20080306258 | Cyclopropane compounds and pharmaceutical use thereof - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 12-11-2008 |
| 20100105894 | Cyclopropane compounds and pharmaceutical use thereof - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 04-29-2010 |
| Patent application number | Description | Published |
|---|
| 20100145750 | Evaluating Service Oriented Architecture Governance Maturity - Evaluating service oriented architecture (‘SOA’) governance maturity including receiving, from a plurality of predetermined stakeholders in the SOA for a plurality of SOA governance capabilities, a stakeholder assessed value representing the current maturity of each of the plurality of SOA governance capabilities; determining, for each of the plurality of SOA governance capabilities in dependence upon the plurality of stakeholder assessed values from the stakeholders, a capability value for each of the plurality of SOA governance capabilities; assigning each of the SOA governance capabilities to a domain; determining, in dependence upon the capability values for each of the plurality of SOA governance capabilities of each domain, a domain maturity value for each domain; and communicating the domain maturity value for each domain to the predetermined stakeholders of the SOA. | 06-10-2010 |
| 20100161454 | Augmenting Service Oriented Architecture Governance Maturity - Augmenting service oriented architecture (‘SOA’) governance maturity including receiving an evaluation of the maturity of the governance of the SOA; identifying, for each governance capability in dependence upon the evaluation of the maturity of the governance capability, one or more predefined risks to the SOA; establishing, for each governance capability in dependence upon the predefined risks to the SOA, a risk value representing the severity of the predefined risks; selecting, for each governance capability in dependence upon the evaluation of the maturity of the governance of the SOA and the predefined risk value, one or more governance work products; and communicating to predetermined stakeholders in the SOA the one or more predefined risks to the SOA identified for each governance capability, the risk value established for each governance capability, and the governance work products selected for each governance capability. | 06-24-2010 |
